IRF3 and viral infectious disease: In contrast to ruxolitinib, inhibition of LGP2 will prevent IRF3 and NF‐κB activation while minimally impacting on viral nucleic acid sensing via RIG‐I and DNA sensors, leaving patients less prone to a wide spectrum of viral infections.